Saama’s Growth Strategy Continues with Addition of Jonathan Burr and Gregory Simpson to Leadership Team

Saama Logo

Campbell, CA (February 18, 2020) - Saama Technologies, Inc. (“Saama”), the number one AI clinical analytics platform company, announced today that it recently expanded its leadership team to include life science technology expert Jonathan Burr as Senior Vice President of Clinical Platform Strategy, and technology marketing leader Gregory T. Simpson as Vice President, Head of Marketing. Jonathan is responsible for growing client adoption of Saama’s existing products, and Greg is charged with building and strengthening the Saama brand. The announcement came at the start of the 11th Annual Summit for Clinical Ops Executives (SCOPE) meeting in Orlando.

“Jonathan and Greg’s vast, collective life science industry experience and impressive individual expertise in sales and marketing, respectively, enhance, compliment and extend the existing talent embodied in Saama’s leadership team,” said Suresh Katta, Saama’s Founder and CEO. “2020 is a year of strategic growth for Saama, and Jonathan and Greg will help fuel the expansion of our market share in furthering our position as the number one AI clinical analytics platform.”

Jonathan has spent two decades as a strategic, global life sciences industry thought leader, with a background in multiple technology domains, including clinical data management, biostatistics, pharmacovigilance, and regulatory. He joins Saama from Accenture Life Sciences, where he served as Managing Director in their London-based Accelerated Research & Development (R&D) Services practice, spearheading R&D technology offerings across Europe. He previously led the Accenture Life Sciences Cloud (ALSC) offering, had sales tenures at Oracle and the contract research organization PPD, and was in software development at Datatrial.

“I was drawn to Saama’s reputation as an innovative data analytics disrupter, and I am very excited to use my expertise for identifying life science technology trends and market opportunities to inspire customers with a vision and roadmap for leveraging Saama’s solutions to meet their clinical development needs,“ said Jonathan.

Greg leads Saama’s overall marketing strategy and execution, with responsibility for building and strengthening the Saama brand, supporting growth strategies, cultivating opportunities, and increasing demand for Saama’s solutions. Prior to joining Saama, Greg led an integrated marketing team at Medidata Solutions, where he built a marketing operations team and led product marketing for the Medidata Clinical Cloud. He previously served as Chief Marketing Officer for Frontwave, and his entrepreneurial experiences include founding a marketing consultancy and serving as the CEO of an internet startup. Greg also held executive marketing, product management, and sales positions at AT&T. Greg received an MBA in Marketing and an MS degree in International Business from Seton Hall University. He has a certification in Executive Leadership from Cornell University, and is currently pursuing a MicroMasters in Artificial Intelligence at Columbia University.

“This is a very dynamic time in Saama’s growth, and marketing has a great opportunity and responsibility to contribute to the company’s success by helping our customers understand how they can overcome the challenges inherent in clinical operations and revolutionize their trials with Saama solutions,” said Greg. “I am delighted that I have an opportunity at Saama to advance these important goals.”

About Saama Technologies, Inc.

Saama is the number one AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Ten of the top 20 pharmaceutical companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at www.saama.com and follow Saama @SaamaTechInc.

About Carrick Capital Partners
Who We Are
A firm of enterprise software, SaaS, and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
Our Approach
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.
Latest News
Infrascale Logo.jpg
C-Level Executives’ Primary Data Protection Concerns Diverge By Sector – Data Security and Encryption Are Most Important in Legal, Data Backup and Recovery Are Top Priority in Education
March 31, 2020
Complia Logo.jpg
Complia Health and the Interim HealthCare franchise network continue a close, longstanding partnership and have extended a many-year agreement following a decade of proven success.
March 5, 2020
Accolade Logo.jpg
Seattle, WA (February 28, 2020) – Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Accolade intends to list its common stock on the Nasdaq Global Select Market under the ticker symbol ACCD.
February 28, 2020